Long Ideas - For many biotechnology investors, there is nothing that matters more than the quality of clinical data. If a company’s data are of quality and the … Continue Reading
Read nowLong Ideas - Cadence (CADX) was a compelling buy last year as the sales ramp for its IV acetaminophen formulation began to improve. A position since Mr. King … Continue Reading
Read nowLong Ideas - Wet macular degeneration is a chronic eye disease that causes vision loss and generally occurs later in life (50+), as blood vessels leak fluid or … Continue Reading
Read nowLong Ideas - Sarepta Therapeutics (SRPT) has become a bit of a lightning rod, with the company’s shares trading near the middle of their 52-week range (from $3.30 … Continue Reading
Read nowMost Popular - Shares of ResMed Inc. (RMD) have finally found their top, peaking at $48.37 in late January before dropping to the $43 level. But the downslide … Continue Reading
Read nowLong Ideas - In medicine, there are certain watershed moments that become an enduring part of medical history, such as the discovery of penicillin, or the eradication of … Continue Reading
Read nowLong Ideas - Endo Pharmaceuticals (NASDAQ:ENDP) reported 3Q 2012 adjusted EPS of $1.28, ahead of the Consensus estimate of $1.26. However, revenues for the period came in at … Continue Reading
Read now